Sanofi will need to provide more evidence supporting the effectiveness of its oral multiple sclerosis drug Aubagio if it wants the treatment to be recommended for use on the NHS in England and Wales.
The National Institute for Health and Care Excellence (NICE), which assesses the cost-effectiveness of treatments for NHS use, released initial draft guidance which requests several clarifications on the evidence submitted by Sanofi, which is looking to market Aubagio (teriflunomide) as a first-line treatment for relapsing remitting multiple sclerosis (RRMS)....... Read More - http://www.ms-uk.org/aubagio
NICE demands more data for Sanofi's oral MS drug Aubagio
NICE demands more data for Sanofi's oral MS drug Aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 1 Replies
- 903 Views
-
Last post by NHE
-
- 1 Replies
- 1147 Views
-
Last post by Petr75
-
- 0 Replies
- 168 Views
-
Last post by NHE
-
- 0 Replies
- 1683 Views
-
Last post by NHE
-
- 0 Replies
- 557 Views
-
Last post by NHE
-
- 1 Replies
- 3184 Views
-
Last post by Tif
-
- 0 Replies
- 167 Views
-
Last post by DIM
-
- 2 Replies
- 1112 Views
-
Last post by DIM
-
- 1 Replies
- 2016 Views
-
Last post by raceya